Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

RxBenefits Launches Patient Assistance Solutions to Curb Specialty Drug Costs for Self-Funded Plans


News Image

At RxBenefits, we leverage our negotiating power, clinical expertise, and exceptional service to do what’s right for our clients and their members.

RxBenefits, the employee benefits industry’s first technology-enabled pharmacy benefits optimizer (PBO), is proud to announce the launch of two new Patient Assistance solutions. Designed to complement RxBenefits’ comprehensive suite of pharmacy solutions, these alternative funding offerings can help reduce specialty drug costs for some patients and plans.

Specialty medications provide breakthrough – sometimes life-saving – treatments for complex, chronic, and rare diseases; however, the cost of these drugs can be prohibitive for self-funded plans. In fact, specialty drugs account for approximately half of U.S. pharmacy drug spend. When such costly drugs are required, plan sponsors are challenged with supporting members and providing a positive experience. The Patient Assistance solutions from RxBenefits address key shortcomings of current patient assistance offerings while also alleviating the financial strain for plan sponsors and patients alike.

With these solutions, patients receive their medications, even if alternative funding is unavailable or the patient doesn’t qualify for need-based assistance. The solutions can offer substantial savings opportunities in the right situations where other market alternatives fall short. These Patient Assistance solutions uphold the RxBenefits approach, ensuring members have a quality service experience while getting the medications they need based on necessary clinical oversight. In keeping with the company’s client-aligned business model, RxBenefits does not receive any fees or commissions related to these solutions.

“At RxBenefits, we leverage our negotiating power, clinical expertise, and exceptional service to do what’s right for our clients and their members,” said Wendy Barnes, CEO, RxBenefits. These Patient Assistance solutions improve clinical oversight and the member experience for alternative funding options.

“This solution set is just one piece of the specialty management puzzle,” Barnes added. “There is no single solution to managing specialty drug costs. A multi-pronged approach to address both specialty drug spend and volatility is critical to doing what’s right for patients by making specialty drugs more accessible and affordable for them and plan sponsors.”

In addition to the new Patient Assistance solutions, the RxBenefits comprehensive specialty pharmacy approach also includes:

  • Optimize 360: RxBenefits’ flagship solution handles every aspect of the pharmacy process, from initial contract negotiations to ongoing plan support and exceptional client and member service. RxBenefits’ client-aligned contracts pass 100% of scaled discounts and rebates to the plan.
  • RxBenefits Protect: A solution that delivers independent clinical expertise, oversight, and intervention to eliminate wasteful spending while protecting the health and safety of plan members. Protect programs are designed and led by independent PharmDs to ensure the plan pays for appropriate and necessary medications, and nothing more.
  • RxPharmacy Assurance: Self-funded employers face skyrocketing prescription benefit costs driven almost exclusively by specialty drug claims. RxPharmacy Assurance mitigates risk from high-cost specialty drug claims and may reduce traditional stop-loss premiums.

Patient Assistance solutions – used in tandem with RxBenefits Protect – provide two options to maximize the benefits of alternative funding while still ensuring patients receive medication quickly. Both options cut costs by tapping into available drug manufacturer assistance dollars, helping vulnerable members access medically necessary and appropriately prescribed high-cost specialty medications. As with any benefit option, Patient Assistance solutions should be evaluated on a case-by-case basis, because not every plan would benefit. RxBenefits can conduct a no-obligation, in-depth analysis for plans to account for money lost from manufacturer rebates if Patient Assistance solutions are considered.

“Self-funded plans require a comprehensive, layered approach to managing specialty spend, and the utilization of alternative funding is one more way RxBenefits helps self-funded plans save on specialty drugs,” said Mark Campbell, SVP of Clinical Solutions, RxBenefits. “We’re excited to work with our preferred providers to ensure available and appropriate savings are passed along to patients and plans.”    

To learn more about RxBenefits’ Patient Assistance solutions, visit rxbenefits.com/solutions/preferred-financial-assistance-solutions. Additional information on the company’s full suite of solutions is available at http://www.rxbenefits.com/solutions.

About RxBenefits

RxBenefits is a technology-enabled pharmacy benefits optimizer (PBO) with more than 800 pharmacy pricing, data, and clinical experts working together to deliver prescription benefit savings to employee benefit consultants and their self-insured clients. With more than 3 million members, RxBenefits brings market-leading purchasing power, independent clinical solutions, and high-touch service to its customers – ensuring that all plan sponsors, regardless of size, can provide an affordable and valuable pharmacy benefit plan to their employees. The company is headquartered in Birmingham, Ala. with a second office in Towson, Md. For more details, visit http://www.rxbenefits.com or follow the company on Facebook, Twitter, and LinkedIn.

Share article on social media or email:



Bola AI Partners with Overjet to Improve Dental Solutions with AI


News Image

Our partnership with Overjet will prove to be a win for both dental professionals and patients.

Bola Technologies, Inc. (Bola AI), a leading provider of voice-AI technology for healthcare and dental care professionals, today announced a pivotal partnership with Overjet, an industry leader in dental artificial intelligence. The union will make the best in cutting-edge AI technology available to dental offices everywhere as part of a preferred pricing package.

Bola AI’s Voice Perio system, which enables dental staff to seamlessly enter periodontal data directly into client PMS and EHR systems in real time, will complement Overjet’s platform, which analyzes dental images, quantifies detected pathology and turns X-rays into powerful patient motivators. The partnership will not only save time for busy hygienists but also lessen the burden of clinical patient documentation for additional office staff.

“Our partnership with Overjet will prove to be a win for both dental professionals and patients,” said Rushi Ganmukhi, CEO and founder of Bola AI. “In conversations with mutual customers, we have heard amazing things about what Overjet has to offer, and it is our pleasure to work with them. Our combined AI technologies perfectly complement one another and will not only deliver amazingly accurate results but also free dentists up to spend more time doing what they love best: serving the healthcare needs of their patients.”

In recent years, AI and deep learning have made incredible strides, with computer vision, language processing and speech recognition achieving near-human levels. Bola AI’s Voice Perio delivers speech accuracy at 99% and allows for variable accents and flexible phrasing while filtering out background noise and nonclinical speech. Bola AI offers the first clinical voice assistant for the dental market to utilize this new age of technology while providing unprecedented ease of use and accuracy.

“At Overjet, we are proud to be at the forefront of utilizing AI to transform dental care,” said Wardah Inam, CEO. “To that end, our mission directly aligns with that of Bola AI. We each provide complementary solutions that appeal to dentists for reasons of speed, accuracy and efficiency that all result in improved quality of care for patients.”

Overjet’s platform improves the patient experience by automatically annotating X-rays to bring color, visibility, transparency and quantification into clinical patient communication — enabling staff to communicate more confidently and effectively, resulting in better case acceptance. Guided by a patient-centric AI, Overjet’s FDA-cleared platform offers more data points in X-rays than previously possible. Overjet identifies key findings that lead to better care and patient outcomes that drive business and revenues forward.

The partnership between Bola AI and Overjet is a boost in the mission to upgrade dental offices across the country struggling with staffing issues while also providing improved infection control and patient education benefits. Their shared goal of being able to offer innovative patient exams without touching a computer is now one step closer to becoming a reality.

About Bola AI

With Bola AI, the future of speech artificial intelligence (AI) is here. By harnessing the power of advanced technologies, this platform can provide efficient, fully integrated and accurate speech solutions for periodontal charting, clinical notes and more. With Bola AI, practices can empower themselves to create a smarter patient experience while improving operational efficiency and driving revenue. Get ready to revolutionize the way your practice operates with Bola AI. Bola AI is headquartered in Boston, MA. For more information, visit bola.ai.

About Overjet

Founded by experts from MIT and the Harvard School of Dental Medicine, Overjet develops accurate and quantified ways to detect pathologies and integrates actionable insights into workflows. Every day, private practices, dental groups and insurance companies rely on the accurate information provided by Overjet to drive care and service to patients. Learn more at overjet.ai.

Share article on social media or email:

Boyd Industries Acquires the Global Surgical SMR Product Line and Now…


Odontogenic sinusitis is fairly common, yet it is prone to misdiagnosis. ODS is uniquely suited to both dental and ENT specialties. A collaborative approach between otolaryngologists and dental…

(PRWeb March 07, 2023)

Read the full story at https://www.prweb.com/releases/boyd_industries_acquires_the_global_surgical_smr_product_line_and_now_caters_to_dental_and_ent_specialists/prweb19209154.htm

Oshi Health Appoints Randy Forman as Chief Commercial Officer and Ryan Powers as Chief Financial Officer


Oshi Health logo

Oshi Health delivers virtual multidisciplinary digestive care that patients love

“Being at the fulcrum of category transformation never gets old, and I can’t wait to help Oshi Health scale the impact of its much needed care to support the larger healthcare transformation towards preventive care,” said Randy Forman, Chief Commercial Officer of Oshi Health.

Oshi Health, the virtual specialty care company transforming gastrointestinal (GI) health outcomes and economics, today announced that two digital health veterans have joined its leadership team: Randy Forman as Chief Commercial Officer and Ryan Powers as Chief Financial Officer. Both have fueled high velocity growth for digital health leaders.     

Riding the momentum from a groundbreaking clinical study that’s fueling innovative contracts with national health plans for Oshi Health, Forman and Powers will play influential roles in the company’s next phase of growth, helping to scale its clinical team nationwide and forging relationships with health plans, employers, channel partners, and provider groups.

Forman was the first commercial employee at Livongo, the digital health pioneer that transformed chronic disease outcomes by combining data and care protocols. There, he created and led the company’s commercial strategy, delivering value across multiple sectors. He has done the same in musculoskeletal care with Vida Health and most recently in mental health with Path.

“This is a pivotal moment for digestive healthcare as the true magnitude of the problem is just becoming clear, a shift towards behavioral treatments emphasizing the mind-gut connection gains traction, and the industry confronts systemic issues like a lack of access and worsening physician shortages,” said Forman. “Being at the fulcrum of category transformation never gets old, and I can’t wait to help Oshi Health scale the impact of its much needed care to support the larger healthcare transformation towards preventive care.”

Powers joins Oshi from NOCD, the digital behavioral health company that he helped grow from 30 to 300 employees in 2 years. Combining finance, strategy and operational lenses, he is uniquely experienced in scaling clinical workforces and operations while instilling quality and preserving culture.

“Oshi Health is building a clinical workforce that could only exist in a virtual care model and redefining the experience of care for patients as well as clinicians,” said Powers. “Its proven clinical outcomes, committed focus, growing network of partners and authentic culture all make it an early market leader in this new era of hybrid collaborative care. I’m thrilled to help Oshi grow and improve the quality of care for all digestive health sufferers.”

“We’ve paved the way for broad access to proven treatments that have not previously been properly supported or incentivized in traditional care while building value for patients, employers, health plans and provider groups,” said Sam Holliday, Oshi Health CEO. “Moments like this are rare – we’re seeing all stakeholders waking up to the urgency of digitally enabled digestive care and Randy and Ryan will ensure that we scale in all of the right ways.”

Oshi Health’s virtual multidisciplinary digestive care model is transforming access and outcomes through high-touch, evidence-based, whole-person care — including often-neglected dietary and psychosocial interventions – as a covered benefit.

About Oshi Health

Oshi Health is a completely redesigned digestive health care experience that transforms access to care, the patient experience, clinical outcomes and healthcare economics. In a high-touch virtual care delivery model, Oshi Health provides diagnosis and integrated care for digestive conditions and empowers people to achieve lasting control of their symptoms. Launched in 2020, Oshi Health works with innovative employers, health insurance partners, health systems and community GI practices to scale access to multidisciplinary care, reduce healthcare costs, and improve the lives of millions of Americans with chronic gastrointestinal diseases. For more information, visit http://www.oshihealth.com.

Share article on social media or email:

Exploring Accessibility in Rare Disease Clinical Research, 4-Day Webinar Series Hosted by Xtalks


Will provide insights into the value of accessibility in rare disease clinical research and how sponsors, patient advocates, researchers and regulators might move from discussion to action.

Each panel in this 4-day webinar series, whether watched individually or in totality with the other panels, will provide insights into the value of accessibility in rare disease clinical research and how sponsors, patient advocates, researchers and regulators might move from discussion to action.

Panel 1: Is Disability Part of Your DEI Planning and Engagement in Rare Disease?

Time: Monday, March 27, 2023, from 10am – 11am EDT

Moderator: Kendall Davis, Director, Advocacy Strategy, Centre for Rare Diseases, ICON plc

Panelists: Erika Heiges, MPH, CHES, Senior Engagement Strategy Lead, Clinical Trial Engagement & Enrollment & DAWN DDiCT Team Lead, Bristol Myers Squibb; James Huang, MD, Director of Student Health Services, Gallaudet University; Amir Rahimi, Senior Manager, Product Communications and Public Affairs, Janssen Pharmaceuticals; Angela Rochelle, Head of Healthcare Diversity Initiatives, Langland; and Grayson Schultz, Writer, Activist and Educator.

Panel 2: Unique Considerations Around Accessibility for Global Clinical Trials Time: Monday, March 27, 2023, from 11am – 12pm EDT

Moderator: Bojana Mirosavljevic, MSc, Director, Patient Advocacy Strategy, ICON plc

Panelists: Nikhil Jayswal, Director, IBD Patient Support Foundation (India); Svenja Kaden, PhD, Vice President, SCN2A Germany e.V.; and Andres Trevino, Patient Advocacy, Chiesi Global Rare Diseases.

Panel 3: Not All Measures Matter: How to Identify Outcomes Measures Appropriate for Your Rare Disease Patient Populations

Time: Tuesday, March 28, 2023, from 10am – 11am EDT

Moderator: Devra Densmore, MPA, Principal Consultant, Elevate Advocacy

Panelists: Gabrielle Conecker, MPH, Executive Director and Co-Founder, Decoding Developmental Epilepsies; Nasha Fitter, MBA, Cofounder and CEO, FOXG1 Research Foundation and VP, Patient Network & Data, Invitae; Tjitske Kleefstra, PhD, Professor, Radboudumc Nijmegen and ErasmusMC, Rotterdam, The Netherlands; Pat Koochaki, PhD, Principal, Patient Centered Outcomes, ICON plc; and Tanja Zdolšek Draksler, PhD, Researcher and Project Manager, Jožef Stefan Institute & Founder and leader, IDefine Europe.

Panel 4: Best Practices in Accessible Clinical Trial Design

Time: Wednesday, March 29, 2023, from 10am – 11am EDT

Moderator: Patti Murphy, Sr. Director of Therapeutic Expertise, ICON plc

Panelists: Rigoberto “Rigo” Garcia, Executive Director, Hemophilia Foundation of Southern California; Veronica Moore, Senior Manager, Patient Advocacy, Horizon Therapeutics; Zo Ratnasi, President & Master Strategist, sixsense strategy group; and Tricha Shivas, Chief Strategy Officer, Foundation for Sarcoidosis Research (FSR).

Panel 5: Accessibility in Rare Disease Paediatric Clinical Trials

Time: Wednesday, March 29, 2023, from 11am – 12pm EDT

Moderator: Firas Taha, MD, Medical Director, Neurology, Medical Affairs, ICON plc

Panelists: Jana Banesh, Director of Therapeutic Expertise, ICON plc; Sarita Edwards, CEO & President, The E.WE Foundation; and Ryan Sheedy, Dad, Rare Disease Caregiver & Founder, mejo.

Panel 6: Where do Expanded Access Programs fit into Trial Accessibility?

Time: Thursday, March 30, 2023, from 10am – 11am EDT

Moderator: Will Maier, Vice President, Center for Rare Diseases, ICON plc

Panelists: Deborah Gelinas, MD, Executive Director, Neuromuscular, argenx; Jack Johnson, Executive Director & Cofounder, Fabry Support & Information Group; and Ray Kaczmarek, Senior Director, Project Operations, Commercialisation & Outcomes, ICON plc.

Panel 7: Meeting Trial Participants Where They’re at: Where DCTs can help Achieve Greater Accessibility

Time: Thursday, March 30, 2023, from 11am – 12pm EDT

Moderator: Afshawn Chakamian, Director of Therapeutic Expertise, ICON plc

Panelists: Ashmee Bharadia, BSc (Hons), Vice President, In Home Services, Accellacare; Sneha Dave, Executive Director, Generation Patient; Craig Lipset, Co-Chair, Decentralized Trials & Research Alliance, Adjunct Assistant Professor, Rutgers University, Vice President, Foundation for Sarcoidosis Research, Managing Partner, Clinical Innovation Partners; and Katie Wright, Person living with VEDS; Host of Staying Connected podcast.

For more information, or to register for this 4-day series starting on Monday, March 27, 2023, visit Rare Disease Week 2023: Exploring Accessibility in Rare Disease Clinical Research.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Riverpoint expands biologic offering with exclusive license of DSM Biomedical’s proprietary Osteoconductive Coating Technology


Doug King, CEO of Riverpoint Medical, stated, “This is a major step for Riverpoint in providing superior solutions and rapidly innovating high-quality medical devices to improve patient outcomes. Our exclusive OC coating technology is a first of its kind in the field of bone fixation and healing.”

Osteoconduction is the ability of bone forming cells to move across a scaffold and replace it with new bone over time. It is well known that many materials commonly used in orthopedic textiles offer low biological activity. By enhancing commonly used materials such as orthopedic fibers and implantable textiles with coatings of widely used Bioceramic materials, the company aspires to create an improved environment for enhanced bone attachment. Osteoconductive coatings are commonly used in orthopedic and dental implants but are not widely available in implantable textiles.

The proprietary OC coating technology created by DSM Biomedical and further developed into a full-scale production line by Riverpoint is a breakthrough in the field of orthopedic space, providing an osteoconductive scaffold at the point of the repair. It offers a revolutionary technology for customers’ products that could benefit from a biological solution. The technology has patents granted and pending worldwide, ensuring exclusivity and adding value to Riverpoint Medical’s partners.

Doug King, CEO of Riverpoint Medical, stated, “This is a major step for Riverpoint in providing superior solutions and rapidly innovating high-quality medical devices to improve patient outcomes. Our exclusive OC coating technology is a first of its kind in the field of bone fixation and healing.”

In conclusion, Riverpoint Medical’s Osteoconductive Coating is an additional step towards offering surgeons and patients improved implantable textiles as a new technology for devices that could benefit from a biological solution. In partnership with DSM Biomedical, the Riverpoint Medical Team is proud to be at the forefront of innovation within the global medical device and healthcare sectors. We are proud to be an exhibitor and sponsor at this year’s AAOS meeting in Las Vegas and encourage interested parties to visit our booth #6635 or DSM’s booth #3032 for additional information.

About Riverpoint Medical

Riverpoint Medical is a leading developer, designer and manufacturer of medical devices focused on advanced surgical fiber related technologies. Riverpoint has a strong history of industry leading product innovation and development across bioabsorbable suture and high strength suture-based implants and constructs. Riverpoint employs a business-to-business model through multiple channels and enjoys partnerships with many of the top Global Medtech Companies in the world. For more information about Riverpoint Medical, please visit http://www.rpmed.com or contact Customer Service at info@rpmed.com or 503-517-8001.

About DSM Biomedical

DSM Biomedical is a part of Royal DSM and the world’s unrivaled biomaterials expert and committed partner in driving sustainable innovation in healthcare. For more than 30 years, the company has been at the forefront of biomaterial science and process innovation, and the leading resource for global medical device and pharmaceutical companies. As a strategic partner with an approach driven not only by market dynamics but by the unique needs of every customer, DSM Biomedical brings an unparalleled breadth of product portfolios, proprietary manufacturing and processing capabilities, world-class IP, and extensive regulatory experience and expertise. Furthermore, DSM Biomedical’s products and services are recognized for their unmatched quality, consistency, and performance in multiple markets across the globe, supporting their company-wide vision of solving the world’s healthcare needs through sustainable science. To learn more, visit http://www.DSMBiomedical.com .

Share article on social media or email:

IPVideo Corporation’s HALO IoT Smart Sensor 3C Named 2023 NSCA Excellence in Product Innovation Award Winner


News Image

IPVideo Corporation is proud to announce that its industry-leading HALO IoT Smart Sensor 3C for safety, health and vape detection has been named an NCSA Excellence in Product Innovation Award winner for Best Retrofit/Installer Friendly Product of 2023. NSCA, the leading not-for-profit association representing the commercial integration industry, announced the winners of its ninth annual Excellence in Product Innovation Awards, a recognition program for manufacturers and products that have a profound impact on systems integrators. The judging panel included NSCA’s director of business resources, the editor of Commercial Integrator, and a panel of integrators from across North America.

“Every year, manufacturers submit more products for consideration, and we’re inspired by the innovation we continue to learn about,” says NSCA Director of Business Resources Mike Abernathy. “As the judging team evaluates each nomination, we see innovation and forward-thinking progress behind every product. It’s clear that manufacturers are working hard to create systems to create the experiences that end-users now expect integrators to help them create.”

“Thank you to the NSCA and to all who voted the HALO Smart Sensor 3C as Best Retrofit/Installer Friendly Product of the Year,” said David Antar, President of IPVideo Corporation. “The HALO Smart Sensor gives integrators a unique offering that solves critical needs of their customers. With HALO 3C we made it easier and faster for our authorized integrators to complete their installations.”

The HALO Smart Sensor 3C boasts new features and benefits for integrators. New surface-mounted hardware allows for the installation of two devices on the same cable run, cutting down on installation time and costs. The new HALO Cloud and HALO Cloud Application offers easy mass deployment and configuration, cloning settings across all devices on the selected network, as well as a means of recognizing recurring revenues post sale. In addition, HALO 3C integrates with most major VMS solutions so multiple units can be added across facilities to provide security in all areas including-g privacy areas where clients do not want video cameras recording.

As an all-in-one solution, the HALO Smart Sensor 3C lets users capture comprehensive health, safety, and vaping awareness using a single device. Designed for use in facilities’ privacy areas, HALO 3C is used in classrooms, hotel rooms, assisted living facilities, and more. Enhanced safety features include a panic button, emergency escape and alert lighting, motion detection, and people counting. In an emergency, facility occupants can trigger the panic button or use the unit’s verbal emergency keyword to call for assistance. The device can also trigger specific lighting colors to signify a specific alert like a gas leak or directional lighting to lead occupants to safety in dangerous situations like a fire or active shooter incident.

The HALO Smart Sensor holds 13 patents with more pending. Learn more at https://halodetect.com/product-info/patents/.

For more information about IPVideo Corporation and the HALO Smart Sensor, visit http://www.ipvideocorp.com and http://www.halodetect.com.

Visit IPVideo Corporation at ISC West 2023, March 29-31, at the Sands Expo in Booth 17099 and see the all-new Sentry ERS Lockdown and Emergency Response System.

About NSCA

The National Systems Contractors Association (NSCA) is the leading not-for-profit association representing the commercial integration industries. The National Systems Contractors Association is a powerful advocate for all who work in the integration industry, including systems contractors/integrators, product manufacturers, consultants, sales representatives, architects, specifying engineers and other allied professionals. NSCA is dedicated to serving its contractor members and all channel stakeholders through advocacy, education, member services, and networking designed to improve business performance. For more information, visit http://www.nsca.org.

About IPVideo Corporation:

An industry pioneer since its introduction of one of the first network-based surveillance recording solutions in 1996, IPVideo Corporation, an Advance Convergence Group (ACG) subsidiary, is now at the forefront of developing unique Event driven AI Security and Safety Solutions that utilize video, audio and sensor technology to effectively mitigate false positives, confirm incidents, accelerate response and deliver long term actionable intelligence. The company’s worldwide client base is served by a network of certified distributors, dealers, and system integrators, who benefit from ongoing corporate support and training. IPVideo Corporation is headquartered in Bay Shore, NY. For more information, visit http://www.ipvideocorp.com.

PR Contact:

Allyson Patanella

Marketing Manager

IPVideo Corporation

631.675.2238

apatanella@ipvideocorp.com

Share article on social media or email: